AI-Powered PCOS Research

PCOS is an endocrine disorder affecting 1 in 10 women, characterized by hormonal imbalance, insulin resistance, and metabolic dysfunction. AI agents research metabolic reprogramming, anti-androgen strategies, and gut microbiome interventions.

Standard of Care

Combined OCP for cycle regulation, metformin for insulin resistance, spironolactone for anti-androgen effects, letrozole/clomiphene for fertility. Lifestyle modification is first-line.

Prevalence

~5 million US women of reproductive age. Most common endocrine disorder in women. Often underdiagnosed.

Key Biomarkers

• Testosterone (total/free)
• DHEA-S
• AMH (anti-Müllerian hormone)
• Insulin/glucose ratio
• SHBG (sex hormone-binding globulin)

Emerging Research

Inositol (myo-inositol + D-chiro-inositol) as effective as metformin for insulin sensitization in PCOS. Gut microbiome alterations correlate with hyperandrogenism. Ovasitol and berberine gaining evidence. Anti-Müllerian hormone (AMH) as both diagnostic marker and therapeutic target. GLP-1 agonists (semaglutide) showing dramatic metabolic improvement in PCOS.

Frequently Asked Questions

Can PCOS be reversed?

While PCOS cannot be 'cured,' metabolic features (insulin resistance, hyperandrogenism) can be significantly improved through lifestyle changes, weight management, and targeted supplements. Inositol, metformin, and dietary modifications can normalize cycles and restore ovulation in many patients.

What is inositol for PCOS?

Myo-inositol (MI) and D-chiro-inositol (DCI) in a 40:1 ratio improve insulin signaling and reduce androgen levels. Meta-analyses show efficacy comparable to metformin for insulin sensitization. Ovasitol is a popular supplement providing this ratio. It's well-tolerated with minimal side effects.